ReviewDer Nervenarzt2013
[Vitamin D and multiple sclerosis : the role for risk of disease and treatment].
Review in Der Nervenarzt, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 17 citations in OpenAlex.
- Exercise enhances the effectiveness of vitamin D therapy in rats with Alzheimer's disease: emphasis on oxidative stress and inflammation.Metabolic brain disease · 2020Article
- Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases.The EPMA journal · 2017Review
- Vitamin D Deficiency in Adult Patients with Schizophreniform and Autism Spectrum Syndromes: A One-Year Cohort Study at a German Tertiary Care Hospital.Frontiers in psychiatry · 2016Article
- Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner.Therapeutic advances in neurological disorders · 2014Review
- Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?The EPMA journal · 2013Article
- Can we prevent or treat multiple sclerosis by individualised vitamin D supply?The EPMA journal · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In addition to its important role in bone metabolism and calcium homeostasis an increasing number of beneficial effects are being attributed to vitamin D. Because of its suggested immunomodulatory capacity vitamin D deficiency or disturbance in the vitamin D metabolism might be a risk factor for the development of autoimmune diseases, such as multiple sclerosis; but supplementation with vitamin D might also be a therapeutic option. Substantial epidemiologic evidence indicates an association between vitamin D levels and risk of multiple sclerosis, suggesting vitamin D to be one of the long searched environmental factors for the development of this most common chronic inflammatory disease of the central nervous system. Less consistent are the available data for modification of the disease course in already established multiple sclerosis.This review highlights possible interactions between vitamin D and multiple sclerosis and focuses on its putative involvement in the pathogenesis and its possible role for treatment of multiple sclerosis. In particular the as yet insufficiently investigated therapeutic aspect is currently being addressed in several high quality clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.